Ardelyx ARDX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ardelyx in its filing.
Tagged under the XBRL concept ardx:ResearchAndDevelopmentExpenseAdjusted.
The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ardelyx's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ardelyx's business segments — R&D?
- Ardelyx (ARDX) reported business segments — R&D of $17.59M in Q1 2026.
- How has Ardelyx's business segments — R&D changed year-over-year?
- Ardelyx's business segments — R&D increased by 55.1% year-over-year, from $11.34M to $17.59M.
- What is the long-term trend for Ardelyx's business segments — R&D?
- Over 3 years (2022 to 2025), Ardelyx's business segments — R&D has grown at a 27.2% compound annual growth rate (CAGR), from $28.78M to $59.22M.
- What does business segments — R&D mean?
- Includes all costs associated with the discovery, clinical development, and regulatory approval processes for new drug candidates. This investment is critical for maintaining a pipeline of innovative therapies and long-term competitive advantage. Higher spending generally indicates an active commitment to expanding the therapeutic portfolio.